Meda is a pharmaceutical company based in Sweden that specializes in the development, manufacturing, and marketing of prescription and over-the-counter (OTC) drugs. The company was founded in 1949 and is headquartered in Solna, Stockholm. Meda offers a wide range of products and services in various therapeutic areas, including respiratory, dermatology, cardiology, pain management, and central nervous system disorders.

The company focuses on developing innovative pharmaceutical solutions that improve patients' quality of life. Some of its popular products include Dymista (for nasal allergies), Bolus (for asthma), and Elidel (for dermatitis). On a global scale, Meda operates in more than 40 countries and has a significant market presence in Europe, North America, and Asia.

The company has several subsidiaries and joint ventures, including Meda Iberia in Spain, Meda Pharma in Germany, and Meda Pharma in China. These partnerships allow Meda to effectively penetrate local markets and cater to the specific needs of each region. Meda has enjoyed a strong market position and has been recognized as one of the leading pharmaceutical companies in the world.

The company has achieved global sales of over $2 billion and has established itself as a formidable competitor in the pharmaceutical industry. Meda's commitment to innovation, product quality, and customer satisfaction has contributed to its success and reputation. In recent years, Meda has undergone significant changes in its strategy and product lineup.

In 2016, the company was acquired by Mylan, a global pharmaceutical company. This acquisition has provided Meda with access to Mylan's extensive global network and resources, further strengthening its position in the market. As of the latest available information, Meda continues to operate as a subsidiary of Mylan.

The company remains committed to its mission of improving healthcare outcomes through the development and marketing of high-quality pharmaceutical products. Meda's focus on innovation and strategic partnerships will likely continue to drive its growth and success in the global pharmaceutical market